Day of Pharma Blockbusters Are Over as Industry Reboots for Agile, Open Innovation

<0> Drugmakers accelerating development by using outside partners, tweaking existing actives, creating new delivery devices, says Lux Research. </0>

Day of Pharma Blockbusters Are Over as Industry Reboots for Agile, Open Innovation

<0> Lux Research, Inc.617-502-5314 </0>

With the drug industry moving away from the all-in-one blockbuster model, pharma companies need to develop more products faster and race to market. As a result, companies are embracing an open innovation structure and scavenging old actives to speed development– to succeed, companies need to get smart at identifying outside partners in areas such as formulation and delivery, says .

“Tailoring the formulation and delivery of therapy provides a cost-effective method to enhance or repurpose drugs, as well as increase relevance when expanding to new markets,” said Yan Xiang Yang, Lux Research Analyst and the lead author of the report titled, “.”

Lux Research positioned technology developers on the Lux Innovation Grid based on their Technical Value and Business Execution – companies that are strong on both axes reach the “Dominant” quadrant. They focused on four markets with the greatest potential – cancer, diabetes, vaccines and pain. Among their findings:

The report, titled “Ranking Emerging Delivery Technologies: Scouring the Toolbox to Find a Nut to Fit the Bolt,” is part of the Lux Research service.

Lux Research provides strategic advice and on‐going intelligence for emerging technologies. Leaders in business, finance and government rely on us to help them make informed strategic decisions. Through our unique research approach focused on primary research and our extensive global network, we deliver insight, connections and competitive advantage to our clients. Visit for more information.

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.